EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.4600
-0.1200 (-7.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.5800
Open1.5700
Bid0.5189 x 2900
Ask0.0000 x 1100
Day's Range1.4300 - 1.6000
52 Week Range1.2400 - 3.9400
Volume925,218
Avg. Volume418,391
Market Cap154.615M
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-1.0600
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.17
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences

    Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of.

  • GlobeNewswire20 days ago

    EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences

    WATERTOWN, Mass., April 02, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • Here's Why EyePoint Pharmaceuticals Saw Its Share Price Drop Today
    Motley Fool25 days ago

    Here's Why EyePoint Pharmaceuticals Saw Its Share Price Drop Today

    A secondary offering raised some cash but diluted current shareholders.

  • GlobeNewswire25 days ago

    EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the pricing of an underwritten public offering of 10,526,500 shares of its common stock at a public offering price of $1.90 per share. The gross proceeds of the offering to the Company are expected to be approximately $20 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty day option to purchase up to an additional 1,578,975 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire26 days ago

    EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT

    EyePoint Pharmaceuticals Inc Six-Month Transition Period Ended December 31, 2018 Earnings Call

  • EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript
    Motley Foollast month

    EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript

    EYPT earnings call for the period ending December 31, 2018.

  • EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
    Zackslast month

    EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 14.29% and 272.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    EyePoint Pharmaceuticals: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 12 cents. The drug delivery technology company posted revenue of $2.4 million in the period. The company's shares ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments

    -YUTIQ™ and DEXYCU™ commercially launched in 1Q2019- -$60 million debt facility secured to support YUTIQ and DEXYCU commercial launches- -Conference call and webcast.

  • Benzingalast month

    The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCUTM (dexamethasone intraocular suspension) 9%

    WATERTOWN, Mass., March 12, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal period ended December 31, 2018 on Thursday, March 14. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A replay of the webcast will also be available on the corporate website at the conclusion of the call.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a $60 million debt facility with CR Group L.P. (CRG) to retire existing debt and provide additional working capital to support the recent launch of YUTIQTM and the anticipated launch of DEXYCUTM expected later in the first quarter of 2019. The remaining net proceeds will provide additional working capital to support EyePoint’s two product launches and general operations. EyePoint also has the option, at its sole discretion, to borrow an additional $15 million prior to June 30, 2019.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it has commercially launched YUTIQTM in the United States. YUTIQ is the Company’s U.S. Food and Drug Administration (FDA) approved, three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company has also launched EyePoint Assist, a program to ensure access to YUTIQ for eligible patients in need of financial assistance.

  • Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline
    Zacks3 months ago

    Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline

    EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors

    WATERTOWN, Mass., Jan. 28, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • ACCESSWIRE4 months ago

    4 Pharma Stocks Raising Eyebrows (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / With the new year only a few days old, the pharmaceutical industry is already buzzing with the excitement surrounding companies who are taking innovative approaches to create a variety of effective treatment options for patients in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Eyepoint Pharmaceuticals, Inc (NASDAQ: EYPT), Cocrystal Pharma Inc (NASDAQ: COCP), and Fred's, Inc (NASDAQ: FRED) are 4 pharma stocks to keep tabs on as the industry moves toward the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company that you may not have heard of, but could potentially benefit from looking into, recognizes the importance of investing in the future of the pharmaceutical industry, and amid this understanding, has made several key announcements in the past few months to show investors, as well as members of its 100,000 patient ecosystem, that the Company is committed to the advancement of this goal.

  • GlobeNewswire4 months ago

    EyePoint Pharmaceuticals Provides 2019 Commercial Update

    WATERTOWN, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today provided a 2019 commercial update. “EyePoint has made significant progress in building its commercial infrastructure in preparation for two ophthalmic product launches in the near-term,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “As a result of the diligence with which our team has worked to execute on commercial manufacturing scale-up, communicate with payors, build our distribution network and our hub for patient and physician support, I am pleased to be able to announce that along with the launch of YUTIQTM in the first quarter of calendar 2019, we also now anticipate launching DEXYCUTM in the first quarter of calendar 2019, earlier than initially expected.

  • GlobeNewswire4 months ago

    EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index

    WATERTOWN, Mass., Dec. 17, 2018 -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
    Zacks5 months ago

    Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

    Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

  • GlobeNewswire5 months ago

    EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of Ron Honig, Esq., as Senior Vice President, General Counsel and Company Secretary, effective immediately.

  • GlobeNewswire5 months ago

    EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)  

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for DEXYCU™ (dexamethasone intraocular suspension) 9%. “The issuance of a specific and permanent J-code for DEXYCU is another key milestone for the Company that allows for a convenient and simplified reimbursement process that is familiar to administering physicians and the greater insurance community,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. The code, J1095, will become effective on January 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective on October 1, 2018.

  • GlobeNewswire5 months ago

    EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    WATERTOWN, Mass., Nov. 06, 2018 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
    Zacks5 months ago

    EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?